{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T01:10:45Z","timestamp":1787015445386,"version":"build-2736575974"},"reference-count":173,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2023,2,8]],"date-time":"2023-02-08T00:00:00Z","timestamp":1675814400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","award":["Unrestricted educational grant"],"award-info":[{"award-number":["Unrestricted educational grant"]}],"id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2023,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>With the increasing number of options for the treatment of moderate\u2010to\u2010severe atopic dermatitis, clinicians need guidance on a practical approach to selecting a systemic agent for specific patient populations. We convened an expert panel consisting of 12 members to conduct a literature review and summarize relevant data related to six scenarios of clinical interest: comorbid asthma, ocular surface disease, history of cancer, past and ongoing infections of interest (including herpes simplex virus, herpes zoster, hepatitis B, and tuberculosis), pregnancy and lactation, and the elderly. We performed a literature search and examined each clinical scenario with respect to three major categories of available systemic agents: traditional systemics (azathioprine, cyclosporine A, methotrexate, and mycophenolate mofetil), Janus kinase inhibitors (abrocitinib, baricitinib, and upadacitinib), and biologics (dupilumab, lebrikizumab, and tralokinumab). The expert panel and steering committee met virtually to review the data and discuss the drafted consensus statements. A modified Delphi process was used to arrive at a set of final consensus statements related to the systemic treatment of AD in these specific patient populations. To provide practical guidance on the choice of systemic therapy for atopic dermatitis in these six topics of clinical interest, 25 expert consensus statements and a summary of the supporting data are presented herein.<\/jats:p>","DOI":"10.1111\/jdv.18922","type":"journal-article","created":{"date-parts":[[2023,1,25]],"date-time":"2023-01-25T03:28:38Z","timestamp":1674617318000},"page":"1135-1148","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":85,"title":["Expert consensus on the systemic treatment of atopic dermatitis in\u00a0special populations"],"prefix":"10.1111","volume":"37","author":[{"given":"D. N.","family":"Adam","sequence":"first","affiliation":[{"name":"Division of Dermatology, Temerty Faculty of Medicine University of Toronto  Toronto Ontario Canada"},{"name":"CCA Medical Research  Ajax Ontario Canada"},{"name":"Probity Medical Research Inc.  Waterloo Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. J.","family":"Gooderham","sequence":"additional","affiliation":[{"name":"Probity Medical Research Inc.  Waterloo Ontario Canada"},{"name":"SKiN Centre for Dermatology  Peterborough Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. R.","family":"Beecker","sequence":"additional","affiliation":[{"name":"Probity Medical Research Inc.  Waterloo Ontario Canada"},{"name":"Division of Dermatology University of Ottawa  Ottawa Ontario Canada"},{"name":"Division of Dermatology The Ottawa Hospital  Ottawa Ontario Canada"},{"name":"Ottawa Hospital Research Institute  Ottawa Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. H.","family":"Hong","sequence":"additional","affiliation":[{"name":"Probity Medical Research Inc.  Waterloo Ontario Canada"},{"name":"Department of Dermatology and Skin Science University of British Columbia  Vancouver British Columbia Canada"},{"name":"Dr. Chih\u2010ho Hong Medical Inc.  Surrey British Columbia Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.\u00a0S.","family":"Jack","sequence":"additional","affiliation":[{"name":"Division of Dermatology McGill University  Montreal Quebec Canada"},{"name":"Research Institute of the McGill University Health Centre  Montreal Quebec Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Jain","sequence":"additional","affiliation":[{"name":"Probity Medical Research Inc.  Waterloo Ontario Canada"},{"name":"Division of Clinical Immunology and Allergy McMaster University  Hamilton Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Lansang","sequence":"additional","affiliation":[{"name":"Division of Dermatology, Temerty Faculty of Medicine University of Toronto  Toronto Ontario Canada"},{"name":"Division of Dermatology Sunnybrook Health Sciences Centre  Toronto Ontario Canada"},{"name":"Division of Dermatology Women's College Hospital  Toronto Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. W.","family":"Lynde","sequence":"additional","affiliation":[{"name":"Division of Dermatology, Temerty Faculty of Medicine University of Toronto  Toronto Ontario Canada"},{"name":"Probity Medical Research Inc.  Waterloo Ontario Canada"},{"name":"Lynde Institute for Dermatology  Markham Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9557-3642","authenticated-orcid":false,"given":"K. A.","family":"Papp","sequence":"additional","affiliation":[{"name":"Probity Medical Research Inc.  Waterloo Ontario Canada"},{"name":"K Papp Clinical Research  Waterloo Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.\u00a0H.","family":"Prajapati","sequence":"additional","affiliation":[{"name":"Probity Medical Research Inc.  Waterloo Ontario Canada"},{"name":"Division of Dermatology, Department of Medicine University of Calgary  Calgary Alberta Canada"},{"name":"Section of Community Pediatrics, Department of Pediatrics University of Calgary  Calgary Alberta Canada"},{"name":"Section of Pediatric Rheumatology, Department of Pediatrics University of Calgary  Calgary Alberta Canada"},{"name":"Dermatology Research Institute  Calgary Alberta Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Turchin","sequence":"additional","affiliation":[{"name":"Probity Medical Research Inc.  Waterloo Ontario Canada"},{"name":"Brunswick Dermatology Centre  Fredericton New Brunswick Canada"},{"name":"Department of Medicine Dalhousie University  Halifax Nova Scotia Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Yeung","sequence":"additional","affiliation":[{"name":"Division of Dermatology, Temerty Faculty of Medicine University of Toronto  Toronto Ontario Canada"},{"name":"Probity Medical Research Inc.  Waterloo Ontario Canada"},{"name":"Division of Dermatology Sunnybrook Health Sciences Centre  Toronto Ontario Canada"},{"name":"Division of Dermatology Women's College Hospital  Toronto Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,2,8]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2013.10.010"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.15928"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1177\/1203475418805721"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/eji.201948156"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.03393-2020"},{"key":"e_1_2_7_7_1","unstructured":"Global Initiative for Asthma.Global Strategy for Asthma Management and Prevention (Updated 2022). Available from:https:\/\/ginasthma.org\/wp\u2010content\/uploads\/2022\/07\/GINA\u2010Main\u2010Report\u20102022\u2010FINAL\u201022\u201007\u201001\u2010WMS.pdf. Accessed 25 Oct 2022."},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2021.09.009"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.waojou.2021.100519"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.2005.00791.x"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/all.14050"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.11.059"},{"key":"e_1_2_7_13_1","unstructured":"Clinicaltrials.gov NCT03809663.A Dose Ranging Placebo\u2010Controlled Double\u2010Blind Study to Evaluate the Safety and Efficacy of Tezepelumab in Atopic Dermatitis. Available from:https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03809663. Accessed: 26 August 2022."},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI124607"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00948-2018"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(18)30184-X"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(16)30265-X"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2017.12.006"},{"key":"e_1_2_7_19_1","unstructured":"Sanofi\u2010aventis Canada Inc.Dupixent (Dupilumab) injection. Product monograph.2022. Available from:https:\/\/pdf.hres.ca\/dpd_pm\/00065186.PDFAccessed: 16 June 2022."},{"key":"e_1_2_7_20_1","unstructured":"Sanofi\u2010aventis U.S.LLC. Dupixent (Dupilumab) injection. Prescribing information.2022. Available from:https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/761055lbl.pdfAccessed 17 June 2022."},{"key":"e_1_2_7_21_1","volume-title":"DUPIXENT (Dupilumab) injection","author":"European Medicines Agency","year":"2022"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2020.06.048"},{"key":"e_1_2_7_23_1","unstructured":"Sanofi\u2010Regeneron.FDA approves Dupixent\u00ae (dupilumab) as first biologic medicine for children aged 6 months to 5\u2009years with moderate\u2010to\u2010severe atopic dermatitis [Press release]. Available from:https:\/\/www.sanofi.com\/en\/media\u2010room\/press\u2010releases\/2022\/2022\u201006\u201007\u201020\u201045\u201000\u20102458243Accessed 18 Jun 2022."},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1804092"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2018.08.005"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1804093"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.20810"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2020.12.059"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.2147\/TCRM.S192392"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/cea.13954"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2021.08.013"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2018.02.012"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2021.02.042"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdermsci.2019.02.002"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.17869"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-019-00465-3"},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2018.10.009"},{"key":"e_1_2_7_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2017.03.003"},{"key":"e_1_2_7_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.11.037"},{"key":"e_1_2_7_40_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.19574"},{"key":"e_1_2_7_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2021.07.036"},{"key":"e_1_2_7_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdin.2021.03.009"},{"key":"e_1_2_7_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.08.051"},{"key":"e_1_2_7_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.09.084"},{"key":"e_1_2_7_45_1","doi-asserted-by":"publisher","DOI":"10.1097\/DER.0000000000000843"},{"key":"e_1_2_7_46_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2022.2035309"},{"key":"e_1_2_7_47_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.15608"},{"key":"e_1_2_7_48_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2019380"},{"key":"e_1_2_7_49_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2021.3023"},{"key":"e_1_2_7_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtos.2020.05.008"},{"key":"e_1_2_7_51_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2020.0796"},{"key":"e_1_2_7_52_1","doi-asserted-by":"publisher","DOI":"10.5021\/ad.2020.32.5.402"},{"key":"e_1_2_7_53_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-016-0170-1"},{"key":"e_1_2_7_54_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2019.1642996"},{"key":"e_1_2_7_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2017.07.007"},{"key":"e_1_2_7_56_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2010.04.027"},{"key":"e_1_2_7_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2011.03.024"},{"key":"e_1_2_7_58_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2009.02.028"},{"key":"e_1_2_7_59_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.17834"},{"key":"e_1_2_7_60_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.03.051"},{"key":"e_1_2_7_61_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2015.02.1116"},{"key":"e_1_2_7_62_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2020.1948"},{"key":"e_1_2_7_63_1","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-2703"},{"key":"e_1_2_7_64_1","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.13857"},{"key":"e_1_2_7_65_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms222413388"},{"key":"e_1_2_7_66_1","unstructured":"FDA FDA\u20102005\u2010D\u20100398.Guidance for Industry \u2010 S8 Immunotoxicity Studies for Human Pharmaceuticals.2006. Available from:https:\/\/www.fda.gov\/regulatory\u2010information\/search\u2010fda\u2010guidance\u2010documents\/s8\u2010immunotoxicity\u2010studies\u2010human\u2010pharmaceuticalsAccessed 16 June 2022."},{"key":"e_1_2_7_67_1","doi-asserted-by":"publisher","DOI":"10.3389\/ftox.2022.866737"},{"key":"e_1_2_7_68_1","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2009101043"},{"key":"e_1_2_7_69_1","doi-asserted-by":"publisher","DOI":"10.1177\/0192623311427711"},{"key":"e_1_2_7_70_1","doi-asserted-by":"publisher","DOI":"10.1177\/1091581810374654"},{"key":"e_1_2_7_71_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-06027-1"},{"key":"e_1_2_7_72_1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2004.049460"},{"key":"e_1_2_7_73_1","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.86434"},{"key":"e_1_2_7_74_1","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2002.120571"},{"key":"e_1_2_7_75_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.14979"},{"key":"e_1_2_7_76_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1809798"},{"key":"e_1_2_7_77_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-017-0636-9"},{"key":"e_1_2_7_78_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2022.04.023"},{"key":"e_1_2_7_79_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.03.050"},{"key":"e_1_2_7_80_1","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2021.1939673"},{"key":"e_1_2_7_81_1","doi-asserted-by":"publisher","DOI":"10.12788\/cutis.0074"},{"key":"e_1_2_7_82_1","first-page":"6","article-title":"Dermatologic applications and safety considerations of Janus kinase inhibitors","volume":"25","author":"Svoboda S","year":"2020","journal-title":"Skin Ther Lett"},{"key":"e_1_2_7_83_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.16116"},{"key":"e_1_2_7_84_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-021-00618-3"},{"key":"e_1_2_7_85_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.16948"},{"key":"e_1_2_7_86_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-021-00726-8"},{"key":"e_1_2_7_87_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2017.10.019"},{"key":"e_1_2_7_88_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2020.08.002"},{"key":"e_1_2_7_89_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-019-00445-7"},{"key":"e_1_2_7_90_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2017.09.052"},{"key":"e_1_2_7_91_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2020.0079"},{"key":"e_1_2_7_92_1","unstructured":"SilverbergJI Tha\u00e7iD SeneschalJ Linda SteinGold AndrewBlauvelt EricSimpsonet al.Efficacy and safety of Lebrikizumab in moderate\u2010to\u2010severe atopic dermatitis: results from two phase 3 randomized double\u2010blinded placebo\u2010controlled trials. Presented at: 2022 American Academy of Dermatology Annual Meeting; 2022 March 25\u201329 Boston Massachusetts."},{"key":"e_1_2_7_93_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30732-7"},{"key":"e_1_2_7_94_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.12.073"},{"key":"e_1_2_7_95_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.20887"},{"key":"e_1_2_7_96_1","doi-asserted-by":"publisher","DOI":"10.1080\/14397595.2017.1392057"},{"key":"e_1_2_7_97_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.idc.2020.02.009"},{"key":"e_1_2_7_98_1","first-page":"CD013206","article-title":"Systemic treatments for eczema: a network meta\u2010analysis","volume":"9","author":"Sawangjit R","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_7_99_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2019.05.007"},{"key":"e_1_2_7_100_1","doi-asserted-by":"publisher","DOI":"10.1002\/cia2.12209"},{"key":"e_1_2_7_101_1","doi-asserted-by":"publisher","DOI":"10.7573\/dic.2021-1-7"},{"key":"e_1_2_7_102_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.xjidi.2021.100003"},{"key":"e_1_2_7_103_1","unstructured":"Aspen Pharmacare Canada Inc.Imuran (Azathioprine). Product monograph.2015. Available from:https:\/\/pdf.hres.ca\/dpd_pm\/00029174.PDFAccessed 16 June 2022."},{"key":"e_1_2_7_104_1","unstructured":"Hoffmann\u2010La Roche Ltd.CellCept. (Mycophenolate Mofetil) injection. Product monograph.2021. Available from:https:\/\/pdf.hres.ca\/dpd_pm\/00063434.PDFAccessed 16 June 2022."},{"key":"e_1_2_7_105_1","unstructured":"Pfizer Canada ULC.Methotrexate Tablets USP. Product monograph.2019. Available fromhttps:\/\/pdf.hres.ca\/dpd_pm\/00013052.PDFAccessed 16 June 2022."},{"key":"e_1_2_7_106_1","doi-asserted-by":"publisher","DOI":"10.1111\/all.12339"},{"key":"e_1_2_7_107_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2015.01.011"},{"key":"e_1_2_7_108_1","doi-asserted-by":"publisher","DOI":"10.1002\/path.4399"},{"key":"e_1_2_7_109_1","doi-asserted-by":"publisher","DOI":"10.2174\/156652407780598557"},{"key":"e_1_2_7_110_1","volume-title":"Cibinqo (Abrocitinib) Tablets. Prescribing information","author":"Pfizer Labs","year":"2022"},{"key":"e_1_2_7_111_1","unstructured":"Eli Lilly Canada Inc.Olumiant (Barcitinib) tablets. Product monograph.2022. Available from:https:\/\/pdf.hres.ca\/dpd_pm\/00066474.PDFAccessed 31 Aug 2022."},{"key":"e_1_2_7_112_1","unstructured":"Novartis Pharmaceuticals Canada Inc.Neoral (Cyclosporine). Product monograph.2015. Available from:https:\/\/pdf.hres.ca\/dpd_pm\/00067198.PDFAccessed 16 June 2022."},{"key":"e_1_2_7_113_1","unstructured":"AbbVie Corporation.Rinvoq (Upadacitinib) tablets. Product monograph.2022. Available from:https:\/\/pdf.hres.ca\/dpd_pm\/00066875.PDFAccessed 16 June 2022."},{"key":"e_1_2_7_114_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2022.01.010"},{"key":"e_1_2_7_115_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2018.11.055"},{"key":"e_1_2_7_116_1","doi-asserted-by":"publisher","DOI":"10.1111\/aji.12514"},{"key":"e_1_2_7_117_1","first-page":"S98","article-title":"Pregnancy, lactation and calcineurin inhibitors","volume":"12","author":"Grimer M","year":"2007","journal-title":"Nephrol Ther"},{"key":"e_1_2_7_118_1","first-page":"249","article-title":"Cyclosporine and lactation: correspondence","volume":"16","author":"Morton A","year":"2011","journal-title":"Nephrol Ther"},{"key":"e_1_2_7_119_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.TP.0000066352.86763.D0"},{"key":"e_1_2_7_120_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.15709"},{"key":"e_1_2_7_121_1","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.22948"},{"key":"e_1_2_7_122_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.crohns.2011.01.009"},{"key":"e_1_2_7_123_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2011.10575.x"},{"key":"e_1_2_7_124_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.crohns.2010.10.005"},{"key":"e_1_2_7_125_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.160.5.610"},{"key":"e_1_2_7_126_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-0528.2006.01232.x"},{"key":"e_1_2_7_127_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780400527"},{"key":"e_1_2_7_128_1","doi-asserted-by":"publisher","DOI":"10.1093\/qjmed\/92.10.551"},{"key":"e_1_2_7_129_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-208840"},{"key":"e_1_2_7_130_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rdc.2016.12.002"},{"key":"e_1_2_7_131_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajmg.a.35223"},{"key":"e_1_2_7_132_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-020-00457-w"},{"key":"e_1_2_7_133_1","unstructured":"European Medicines Agency.Cibinqo (Abrocitinib). European Public Assessment Report.2022. Available from:https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/cibinqoAccessed 20 June 2022."},{"key":"e_1_2_7_134_1","unstructured":"European Medicines Agency.Olumiant (Barcitinib). European Public Assessment Report.2022. Available from:https:\/\/www.ema.europa.eu\/en\/documents\/overview\/olumiant\u2010epar\u2010medicine\u2010overview_en\u20100.pdfAccessed 20 June 2022."},{"key":"e_1_2_7_135_1","unstructured":"Lilly USA LLC.Olumiant (Barcitinib) tablets. Prescribing information.2022. Available from:https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/207924s006lbl.pdfAccessed 17 June 2022."},{"key":"e_1_2_7_136_1","unstructured":"AbbVie Inc.Rinvoq (Upadacitinib) tablets. Prescribing information.2022. Available from:https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/211675s007lbl.pdfAccessed 17 June 2022."},{"key":"e_1_2_7_137_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijwd.2016.12.003"},{"key":"e_1_2_7_138_1","unstructured":"European Medicines Agency.Adtralza (Tralokinumab). European Public Assessment Report.2021. Available from:https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/adtralzaAccessed 20 June 2022."},{"key":"e_1_2_7_139_1","unstructured":"LEO Pharma Inc.Adbry (Tralokinumab) injection. Prescribing information.2022. Available from:https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfmAccessed 17 June 2022."},{"key":"e_1_2_7_140_1","unstructured":"LEO Pharma Inc.Adtralza (Tralokinumab) injection. Product monograph.2021. Available from:https:\/\/pdf.hres.ca\/dpd_pm\/00063207.PDFAccessed 16 June 2022."},{"key":"e_1_2_7_141_1","unstructured":"European Medicines Agency.Dupixent Assessment Report.2017. Available from:https:\/\/www.ema.europa.eu\/en\/documents\/assessment\u2010report\/dupixent\u2010epar\u2010public\u2010assessment\u2010report_en.pdfAccessed 13 Jun 2022."},{"key":"e_1_2_7_142_1","unstructured":"European Medicines Agency.Dupixent CHMP assessment report on extension of marketing authorisation and an extension of indication variation.2019. Available from:https:\/\/www.ema.europa.eu\/en\/documents\/variation\u2010report\/dupixent\u2010h\u2010c\u20104390\u2010x\u20100004\u2010g\u2010epar\u2010assessment\u2010report\u2010extension_en.pdfAccessed 13 Jun 2022."},{"key":"e_1_2_7_143_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13223-022-00650-w"},{"key":"e_1_2_7_144_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.16235"},{"key":"e_1_2_7_145_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2020.08.001"},{"key":"e_1_2_7_146_1","first-page":"5448","article-title":"Safety profile of Dupilumab during pregnancy: a data mining and disproportionality analysis of over 37,000 reports from the WHO individual case safety reporting database (VigiBase\u2122)","volume":"25","author":"Khamisy\u2010Farah R","year":"2021","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"e_1_2_7_147_1","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01208-2019"},{"key":"e_1_2_7_148_1","first-page":"54","article-title":"Biological agents in pregnancy and lactation \u2013 a rational approach","volume":"1","author":"Prabhu SS","year":"2019","journal-title":"J Skin Sex Transm Dis"},{"key":"e_1_2_7_149_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.621247"},{"key":"e_1_2_7_150_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22115729"},{"key":"e_1_2_7_151_1","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.14891"},{"key":"e_1_2_7_152_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2020.2940"},{"key":"e_1_2_7_153_1","doi-asserted-by":"publisher","DOI":"10.1097\/DER.0000000000000686"},{"key":"e_1_2_7_154_1","first-page":"47","article-title":"Atopic dermatitis in the elderly: a review of clinical and pathophysiological hallmarks","volume":"182","author":"Williamson S","year":"2019","journal-title":"Br J Dermatol"},{"key":"e_1_2_7_155_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40266-020-00750-5"},{"key":"e_1_2_7_156_1","doi-asserted-by":"publisher","DOI":"10.1097\/DER.0000000000000845"},{"key":"e_1_2_7_157_1","doi-asserted-by":"publisher","DOI":"10.1111\/ced.14260"},{"key":"e_1_2_7_158_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-021-00597-5"},{"key":"e_1_2_7_159_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.17094"},{"key":"e_1_2_7_160_1","first-page":"23","article-title":"Mycophenolate mofetil therapy for moderate to severe atopic dermatitis","volume":"32","author":"Murray ML","year":"2006","journal-title":"Clin Exp Dermatol"},{"key":"e_1_2_7_161_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2010.03921.x"},{"key":"e_1_2_7_162_1","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2003.137"},{"key":"e_1_2_7_163_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0733-8635(05)70141-8"},{"key":"e_1_2_7_164_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2022.0434"},{"key":"e_1_2_7_165_1","first-page":"191","article-title":"Severe harm and death associated with errors and drug interactions involving low\u2010dose methotrexate","volume":"43","author":"Grissinger M","year":"2018","journal-title":"Pharm Ther"},{"key":"e_1_2_7_166_1","unstructured":"European Medicines Agency.Jylamvo (Methotrexate). European Public Assessment Report.2022. Available from:https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/jylamvoAccessed 20 June 2022."},{"key":"e_1_2_7_167_1","unstructured":"Par Pharmaceutical.Methotrexate tablets. Prescribing information.2020. Available from:https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfmAccessed 17 June 2022."},{"key":"e_1_2_7_168_1","doi-asserted-by":"publisher","DOI":"10.1684\/ejd.2019.3609"},{"key":"e_1_2_7_169_1","unstructured":"Sebela Pharmaceuticals Inc.Imuran (Azathioprine) tablets. Prescribing information.2018. Available from:https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/016324s039lbl.pdfAccessed 29 June 2022."},{"key":"e_1_2_7_170_1","unstructured":"European Medicines Agency.Jayempi (Azathioprine). European Public Assessment Report.2022. Available from:https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/jayempiAccessed 20 June 2022."},{"key":"e_1_2_7_171_1","unstructured":"European Medicines Agency.CellCept (Mycophenolate Mofetil). European Public Assessment Report.2022. Available from:https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/cellceptAccessed 20 June 2022."},{"key":"e_1_2_7_172_1","unstructured":"Hoffmann\u2010La Roche Inc.CellCept (Mycophenolate Mofetil). Prescribing information.2022. Available from:https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/050722s050 050723s050 050758s048 050759s055lbl.pdfAccessed 17 June 2022."},{"key":"e_1_2_7_173_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2678"},{"key":"e_1_2_7_174_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2015.10.027"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.18922","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jdv.18922","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.18922","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,20]],"date-time":"2023-08-20T04:36:38Z","timestamp":1692506198000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jdv.18922"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,8]]},"references-count":173,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["10.1111\/jdv.18922"],"URL":"https:\/\/doi.org\/10.1111\/jdv.18922","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,8]]},"assertion":[{"value":"2022-10-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-01-16","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-02-08","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}